Metastatic Prostate Cancer Clinical Trials

75 recruitingLast updated: June 17, 2026

There are 75 actively recruiting metastatic prostate cancer clinical trials across 33 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Madrid, Spain, Baltimore, Maryland, United States. Updated daily from ClinicalTrials.gov.


Metastatic Prostate Cancer Trials at a Glance

75 actively recruiting trials for metastatic prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Boston, Madrid, and Baltimore. Lead sponsors running metastatic prostate cancer studies include Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Novartis Pharmaceuticals, and AstraZeneca.

Browse metastatic prostate cancer trials by phase

Treatments under study

About Metastatic Prostate Cancer Clinical Trials

Looking for clinical trials for Metastatic Prostate Cancer? There are currently 58 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 75 trials

Recruiting
Phase 1Phase 2

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Metastatic Prostate Cancer
AstraZeneca42 enrolled8 locationsNCT07529717
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

Non-metastatic Prostate CancerLocally Recurrent Prostate Cancer
Alpha Tau Medical LTD.10 enrolled1 locationNCT06202248
Recruiting
Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled26 locationsNCT05800665
Recruiting
Phase 1Phase 2

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Metastatic Prostate Cancer
AstraZeneca177 enrolled52 locationsNCT07181161
Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.260 enrolled2 locationsNCT07567846
Recruiting
Phase 1

A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer (mCRPC)
Novartis Pharmaceuticals15 enrolled4 locationsNCT07174063
Recruiting
Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled147 locationsNCT05939414
Recruiting
Early Phase 1

First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer

Metastatic Breast CancerCancerMetastatic Prostate Cancer+5 more
Integrated Haematology and Oncology Network20 enrolled1 locationNCT07608848
Recruiting

Collection of Blood From Patients With Prostate Cancer

Prostate CancerMetastatic Prostate CancerCancer of Prostate+2 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT00923221
Recruiting
Phase 2

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Metastatic Prostate Cancer
University Health Network, Toronto132 enrolled2 locationsNCT05404139
Recruiting
Not Applicable

HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)

Oligometastatic Prostate Cancer (OMPC)Prostate Cancer Metastatic Disease
Institut Cancerologie de l'Ouest18 enrolled1 locationNCT06978296
Recruiting
Phase 3

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

Metastatic Prostate Cancer
University of Utah200 enrolled1 locationNCT06112990
Recruiting
Phase 1

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

Prostate CancerMetastatic Prostate Cancer
University of California, San Francisco30 enrolled1 locationNCT07145177
Recruiting
Phase 4

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

Metastatic Breast CancerMetastatic Prostate Cancer
Ottawa Hospital Research Institute50 enrolled3 locationsNCT07252726
Recruiting
Not Applicable

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

Metastatic Breast CancerMetastatic Prostate Cancer
Institut Claudius Regaud54 enrolled1 locationNCT06904625
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Castration Resistant Metastatic Prostate Cancer+2 more
Aktis Oncology, Inc.138 enrolled2 locationsNCT07581184
Recruiting
Phase 1Phase 2

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
University College, London60 enrolled1 locationNCT07414940
Recruiting
Not Applicable

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Oligometastatic Prostate Cancer
British Columbia Cancer Agency168 enrolled4 locationsNCT04610372
Recruiting
Not Applicable

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Metastatic Prostate CancerCastrate Sensitive Prostate Cancer
Paul Viscuse24 enrolled1 locationNCT06429813
Recruiting
Phase 3

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Metastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Canadian Cancer Trials Group236 enrolled14 locationsNCT06439225